sulfasalazine has been researched along with Malignant Melanoma in 1 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muthusamy, V | 1 |
| Piva, TJ | 1 |
1 other study available for sulfasalazine and Malignant Melanoma
| Article | Year |
|---|---|
UVB-stimulated TNFα release from human melanocyte and melanoma cells is mediated by p38 MAPK.
Topics: Anisomycin; Anthracenes; Cell Line, Tumor; Cell Survival; Humans; Imidazoles; Interleukin-1alpha; MA | 2013 |